{"id":3111,"date":"2026-03-31T16:26:38","date_gmt":"2026-03-31T16:26:38","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=3111"},"modified":"2026-03-31T16:26:38","modified_gmt":"2026-03-31T16:26:38","slug":"major-drug-deal-gilead-sciences-acquires-new-treatment-for-immune-diseases","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/major-drug-deal-gilead-sciences-acquires-new-treatment-for-immune-diseases\/","title":{"rendered":"Major Drug Deal: Gilead Sciences Acquires New Treatment for Immune Diseases"},"content":{"rendered":"

Gilead Sciences, a leading pharmaceutical company, has just made a big investment in a new type of treatment for immune system diseases. The company is paying $2 billion to acquire Ouro Medicines, a smaller biotech company. As part of this deal, Gilead gains access to a promising experimental drug called OM336, also known as gamgertamig. This drug is designed to work in a unique way by targeting both B cells and T cells in the immune system, which could make it a first-choice treatment for certain diseases. <\/p>\n

Gilead will pay $1.675 billion upfront, with the possibility of paying another $500 million later if the drug meets specific development and sales goals. The drug is currently in early stages of testing (Phase I\/II) and has already shown impressive results in a trial for a rare, severe immune disease. In this trial, a single treatment cycle of OM336 led to significant improvement and a good safety profile. <\/p>\n

Dr. Dietmar Berger, Gilead\u2019s Chief Medical Officer, explained that OM336 works by targeting a specific protein called BCMA, which is found on B cells. This approach is different from existing treatments and could provide long-lasting control of the disease. He said, ‘BCMA is a proven target, and early data shows that this type of treatment could revolutionize how we manage autoimmune<\/a> diseases. This fits perfectly with our goal to develop innovative treatments that could change the standards of care.’<\/p>\n

Gilead and another company, Galapagos, plan to work together on developing OM336 as part of this acquisition. The deal still needs to meet standard conditions before it can be finalized.<\/p>\n

This news comes at a time when other major pharmaceutical companies are also investing in similar treatments. For example, Sanofi recently secured rights to another T cell engager, called KT501, through a licensing agreement with Kali Therapeutics. Sanofi agreed to pay up to $1.05 billion if the drug meets development and sales milestones. The CEO of Kali Therapeutics, Weihao Xu, believes that KT501 could address unmet needs in autoimmune diseases by effectively reducing harmful B cell populations while minimizing side effects like excessive immune reactions.<\/p>\n

This is an exciting time for patients with immune-mediated diseases, as these new treatments could offer more effective and safer options in the future.<\/p>\n","protected":false},"excerpt":{"rendered":"

Gilead Sciences, a leading pharmaceutical company, has just made a big investment in a new type of treatment for immune […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3111","post","type-post","status-publish","format-standard","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3111"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3111\/revisions"}],"predecessor-version":[{"id":3117,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3111\/revisions\/3117"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}